Skip to main content
Gerard Gallagher on Muck Rack

Gerard Gallagher

Verified
Philadelphia
As seen in: Healio, Healio Primary Care, Infectious Diseases News, LinkedIn, Healio Cardiac/Vascular Intervention, Healio Gastroenterology, HemOnc Today, Orthopedics Today, Citeline, Salt and Light Magazine, Salt + Light Media
*Inactive account* Executive editor, @InfectDisNews/@IDinChildren. Past: @CBSSports, The Sports Network. I've covered 5 Olympics & 9 IDWeeks. "JEH-rid." he/him
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Gerard

Contact Gerard, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

FDA approves Xocova for COVID-19 prevention after exposure

|
By Gerard Gallagher Verified
| Infectious Diseases News Verified
FDA approves Xocova for COVID-19 prevention after exposure Add topic to email alerts Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Subscribe We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio Key takeaways: Xocova (ensitrelvir, Shionogi) is the first approved post-exposure prophylaxis for COVID-19.
Open in Who Shared Issue with article?

Capvaxive approved for children at high risk for pneumococcal disease

|
By Gerard Gallagher Verified, Sara Kellner Verified
| Healio Verified
Capvaxive approved for children at high risk for pneumococcal disease Add topic to email alerts Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Subscribe We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Open in Who Shared Issue with article?

FDA approves Xocova for COVID-19 prevention after exposure

|
By Gerard Gallagher Verified
| Infectious Diseases News Verified
FDA approves Xocova for COVID-19 prevention after exposure Add topic to email alerts Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Subscribe We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio Key takeaways: Xocova (ensitrelvir, Shionogi) is the first approved post-exposure prophylaxis for COVID-19.
Open in Who Shared Issue with article?
See all 721 articles